Media Update

NTI was just featured in The Australian

Below is the link that will avoid the pay wall.
http://webcache.googleusercontent.com/search?q=cache:hKLpN9kzQ5wJ:www.theaustralian.com.au/business/companies/outstanding-results-on-autism-device-boosts-neurotech/news-story/5254ae0eebd078356127cc99c87aaa12 &cd=2&hl=en&ct=clnk&gl=au

‘Outstanding’ results on autism device boosts Neurotech

​

Neurotech founder and drug discoverer Dr Adrian Attard Trevisan (right) with chief executive Wolfgang Storf. (Picture: George Scintilla)​

• The Australian​
• 1:29PM September 27, 2017​
• SARAH-JANE TASKER
  
  Reporter
  Sydney
  @SarahJaneTasker​

Positive test results on a device that aids kids with autism has boosted the share price of Australian-listed minnow Neurotech, with experts hailing the early findings as “outstanding”.
Neurotech (NTI), which is developing an at-home product to help children with autism, enjoyed a more than 60 per cent boost to its shares today after revealing early results of the study.
The company, which listed on the Australian market last November, has developed Mente Autism, which is a clinical-quality device that uses neurofeedback technology to help children with autism. Designed for home use, Mente Autism helps relax the minds of children on the spectrum, which in turns helps them to focus better and engage positively with their environment.
The findings of the study on the device, conducted by US-based Carrick Institute, were presented at a mental health conference last week.
Ahmed Hankir, a senior research Fellow at the Bedfordshire Centre for Mental Health Research in association with the University of Cambridge, said the study using the Mente Autism device was one of the most exciting investigations this year.
“The changes observed in autistic children after a 12-week clinical trial are outstanding with many of the children with autism scoring in a normal range after the treatment,” he said.
Professor Frederick Carrick, a senior research fellow at BCMHR, said the study involved dividing children that had a documented diagnosis of Autism Spectrum Syndrome into two groups. One group received a real treatment and the other group received a placebo treatment.
“The study is ongoing but half of the children in our study have completed it and we have observed major positive changes in the children in the active arm of the study and no statistical changes in the control group of children that did not receive the active treatment,” he said.
The study is expected to be finalised by the end of the year.
Neurotech appointed an Australian distributor for the product last month, making it accessible domestically.